Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
J Pediatr ; 257: 113304, 2023 06.
Article in English | MEDLINE | ID: mdl-36528053

ABSTRACT

OBJECTIVE: Determine the clinical safety and feasibility of implementing a telemedicine and medication delivery service (TMDS) to address gaps in nighttime access to health care for children in low-resource settings. STUDY DESIGN: We implemented a TMDS called 'MotoMeds' in Haiti as a prospective cohort study. A parent/guardian of a sick child ≤ 10 years contacted the call center (6 PM-5 AM). A nurse provider used decision support tools to triage cases (mild, moderate, or severe). Severe cases were referred to emergency care. For nonsevere cases, providers gathered clinical findings to generate an assessment and plan. For cases within the delivery zone, a provider and driver were dispatched and the provider performed a paired in-person exam as a reference standard for the virtual call center exam. Families received a follow-up call at 10 days. Data were analyzed for clinical safety and feasibility. RESULTS: A total of 391 cases were enrolled from September 9, 2019, to January 19, 2021. Most cases were nonsevere (92%; 361); household visits were completed for 89% (347) of these cases. Among the 30 severe cases, 67% (20) sought referred care. Among all cases, respiratory problems were the most common complaint (63%; 246). At 10 days, 95% (329) of parents reported their child had "improved" or "recovered". Overall, 99% (344) rated the TMDS as "good" or "great". The median phone consultation time was 20 minutes, time to household arrival was 73 minutes, and total case time was 114 minutes. CONCLUSION: The TMDS was a feasible health care delivery model. Although many cases were likely self-limiting, the TMDS was associated with high rates of reported improvement in clinical status at 10 days. TRIAL REGISTRATION: clinicaltrials.gov: NCT03943654.


Subject(s)
Telemedicine , Child , Humans , Feasibility Studies , Pilot Projects , Prospective Studies , Referral and Consultation
3.
PLoS Negl Trop Dis ; 15(6): e0009494, 2021 06.
Article in English | MEDLINE | ID: mdl-34133422

ABSTRACT

We report the identification of two orthobunyaviruses, Melao virus (MELV) and Oropouche virus (OROV), in plasma specimens from Haitian children with acute febrile illness who presented during outbreaks caused by alpha- and flaviviruses in 2014. Heretofore not described as a human pathogen, MELV was isolated in cell culture from the plasma of five case patients. OROV RNA was detected in the plasma of an additional child, using an unbiased sequencing approach, with phylogenetic inference suggesting a close relationship with strains from Brazil. Abdominal pain was reported by four case patients with MELV infections, with lymphadenopathy noted in two cases. Our findings document the occurrence of these orthobunyaviruses within the Caribbean region and highlight the critical importance of surveillance with viral genome sequence analyses to identify outbreaks caused by these and other emerging viruses.


Subject(s)
Bunyaviridae Infections/epidemiology , Orthobunyavirus/isolation & purification , Abdominal Pain , Adolescent , Bunyaviridae Infections/blood , Bunyaviridae Infections/diagnosis , Child , Child, Preschool , Communicable Diseases, Emerging/virology , Female , Genome, Viral , Haiti/epidemiology , Humans , Lymphadenopathy , Male , Orthobunyavirus/classification , Orthobunyavirus/genetics , Phylogeny , RNA, Viral/genetics
5.
J Speech Lang Hear Res ; 60(1): 231-237, 2017 01 01.
Article in English | MEDLINE | ID: mdl-28056149

ABSTRACT

Purpose: The objective of this study was to use cross-sectional, nationally representative data to examine the relationship between self-reported hearing impairment and undetected diabetes, hypertension, hypercholesterolemia, and chronic kidney disease. Method: We analyzed the National Health and Nutrition Examination Survey for the years 2007-2012 for individuals 40 years of age and older without previously diagnosed cardiovascular disease. Analyses were conducted examining hearing impairment and undiagnosed disease. Results: The unweighted sample size was 9,786, representing 123,444,066 Americans. Hearing impairment was reported in 10.2% of the individuals. In unadjusted analyses, there was no significant difference between adults with hearing impairment and adults with typical hearing for undiagnosed diabetes, hypertension, or hypercholesterolemia. A higher proportion of adults with hearing impairment than adults with typical hearing had undiagnosed chronic kidney disease (20.1% vs. 10.7%; p = .0001). In models adjusting for demographics and health care utilization, hearing impairment was associated with a higher likelihood of having undiagnosed chronic kidney disease (odds ratio = 1.53, 95% CI [1.23, 1.91]). Conclusions: Individuals with hearing impairment are more likely to have undiagnosed chronic kidney disease. Hearing impairment may affect disclosure of important signs and symptoms as well as the comprehension of medical conversations for chronic disease management. General practitioners can play a critical role in improving medical communication by responding with sensitivity to the signs of hearing impairment in their patients.


Subject(s)
Diabetes Mellitus/epidemiology , Hearing Loss/complications , Hearing Loss/epidemiology , Hypercholesterolemia/epidemiology , Hypertension/epidemiology , Renal Insufficiency, Chronic/epidemiology , Adult , Aged , Cross-Sectional Studies , Diabetes Mellitus/diagnosis , Diagnostic Errors , Female , Humans , Hypercholesterolemia/complications , Hypercholesterolemia/diagnosis , Hypertension/complications , Hypertension/diagnosis , Male , Middle Aged , Odds Ratio , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/diagnosis , Self Report , United States/epidemiology
6.
Am J Trop Med Hyg ; 90(1): 80-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24218408

ABSTRACT

We conducted a longitudinal analysis of 117 lymphedema patients in a filariasis-endemic area of Haiti during 1995-2008. No difference in lymphedema progression between those who received or did not receive mass drug administration (MDA) was found on measures of foot (P = 0.24), ankle (P = 0.87), or leg (P = 0.46) circumference; leg volume displacement (P = 0.09), lymphedema stage (P = 0.93), or frequency of adenolymphangitis (ADL) episodes (P = 0.57). Rates of ADL per year were greater after initiation of MDA among both groups (P < 0.01). Nevertheless, patients who received MDA reported improvement in four areas of lymphedema-related quality of life (P ≤ 0.01). Decreases in foot and ankle circumference and ADL episodes were observed during the 1995-1998 lymphedema management study (P ≤ 0.01). This study represents the first longitudinal, quantitative, leg-specific analysis examining the clinical effect of diethylcarbamazine on lymphedema progression and ADL episodes.


Subject(s)
Albendazole/therapeutic use , Diethylcarbamazine/therapeutic use , Elephantiasis, Filarial/drug therapy , Inflammation/pathology , Ivermectin/therapeutic use , Adolescent , Adult , Aged , Albendazole/administration & dosage , Anthelmintics/administration & dosage , Anthelmintics/therapeutic use , Child , Diethylcarbamazine/administration & dosage , Elephantiasis, Filarial/epidemiology , Elephantiasis, Filarial/pathology , Female , Haiti/epidemiology , Humans , Ivermectin/administration & dosage , Male , Middle Aged , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...